Gates MRI and UCSF join the TBDA
The TBDA welcomed two new members after the October 2021 semi-annual meeting.
The team specializes in data-driven pharmacokinetic-pharmacodynamic (PK/PD) modeling and simulation as a resource for improving global health. They apply quantitative, model-based principles of drug response and disease dynamics to optimize doses, dosing schedules, drug regimens, and treatment durations, potentially bringing novel therapies to patients with unmet needs.
The team specializes in evaluating novel biomarkers of drug and drug regimen effect both pre-clinically and clinically, working with collaborators to improve and develop existing and newer animal models, evaluating drug candidates and targets to enhance treatment shortening for TB, and providing expertise and a potential development pathway for TBDA members’ drug candidates.